Progress of drug therapy for refractory pituitary adenomas
ZHANG Cheng
WANG Ji-chao
Abstract：Pituitary adenoma is a common neuroendocrine tumor in the brain.The majority can be cured via surgery,medication,or radiotherapy.Nevertheless,a small portion of pituitary adenomas exhibit invasive growth and a relatively rapid growth rate.Even when combined with multiple approaches such as surgery,medication,and radiotherapy,tumor progression cannot be controlled,leading to a poor prognosis and even patient mortality.These are referred to as refractory pituitary adenomas.The clinical treatment of such cases poses a significant challenge and typically requires multimodal therapy.Recently,as research on the microenvironment of pituitary adenomas has gradually deepened,an increasing number of studies have been conducted on the anti-tumor effects of chemotherapy drugs(such as temozolomide,capecitabine,and everolimus),immunotherapy,and peptide receptor radionuclide therapy for refractory pituitary tumors.The prognosis of these patients has been significantly improved.This article provides a review of the progress in drug treatment for refractory pituitary adenomas,summarizes comprehensive information regarding drug treatment and its efficacy,and offers a reference for clinical practice.
Keywords：Pituitary adenomaRefractory pituitary adenomaDrug treatment
Publication Date：2024-10-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 616-619 )